Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Status:
Completed
Trial end date:
2020-11-25
Target enrollment:
Participant gender:
Summary
To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in
combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in
order to determine the maximum tolerated dose and select the recommended Phase 2 dose.